Padcev

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

News

NICE backs bladder cancer duo that can double survival

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.

News

Padcev/Keytruda extends survival in early bladder cancer

Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.

News

Astellas raises Padcev forecasts on bladder cancer data

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m

News

CHMP turns down Neuraxpharm, Apellis drugs

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will a

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

EMA starts review of 'transformative' bladder cancer therapy

NICE backs bladder cancer duo that can double survival

Padcev/Keytruda extends survival in early bladder cancer

Astellas raises Padcev forecasts on bladder cancer data

CHMP turns down Neuraxpharm, Apellis drugs

BMS chases MSD/Seagen with first-line bladder cancer filing

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Padcev

Editor's Picks